

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**THE DISPOSITION OF METRONIDAZOLE IN GOATS  
AND ITS RELEVANCE TO THE TREATMENT OF  
ANAEROBIC INFECTIONS**

A THESIS

PRESENTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS

FOR THE DEGREE OF

MASTER OF VETERINARY SCIENCE

AT

MASSEY UNIVERSITY

**Elizabeth Amanda Dillon**

**1988**

## ABSTRACT

The recent commercial developments in goat farming in New Zealand, have led to an increase in the value of individual goats and to a growing interest in caprine diseases.

The importance of anaerobic bacteria other than the clostridia, as potential pathogens in humans and animals, has also only recently been recognised, even though anaerobic bacteria have been identified since 1861. Various members of this bacterial group are known to be involved in different conditions of goats, particularly in wound and foot infections.

Metronidazole (Flagyl<sup>1</sup>) is a bactericidal agent which has a specific action against anaerobic micro-organisms. This drug is already widely used in the treatment of selected diseases in dogs, cats and humans, but there was little information available on its use in goats.

The study which forms the basis of this thesis, was to investigate the disposition of metronidazole in eight goats. Both IV and IM routes of administration were studied in the form of a cross-over experiment. Silicone tubing "cages" were implanted subcutaneously, so that the metronidazole concentration versus time profile could be determined, both in serum and in interstitial fluid.

The analysis of serum and tissue cage fluid samples was undertaken using a high pressure liquid chromatography unit, which proved to be reliable over the range of concentrations tested. The system consisted of a Waters Model 6000 A solvent delivery system, a U6K injector, a Z-module radial compression separation system and a Waters programmable automator, Model 710. The mobile phase used was a 75:25 mixture of aqueous potassium hydrogen phosphate and methyl alcohol; this was adjusted to a running speed of 1.5 mls per min. A 450 variable wavelength detector was set at either 0.01 or 0.04 absorbance units, and a constant wavelength of 312 nm.

Given these concentration profiles, a full pharmacokinetic analysis was carried out using standard statistical procedures. The following values were determined:

---

1. 'Flagyl', May & Baker (NZ) Ltd.

maximum serum and tissue cage fluid concentrations ( $C_{\max IV}$ ,  $C_{\max IM}$ ,  $C_{\max IV_{tc}}$ ), time to maximum serum and tissue cage concentration ( $T_{\max IV}$ ,  $T_{\max IM}$ ,  $C_{\max IM_{tc}}$ ,  $T_{\max IM_{tc}}$ ), serum concentration (extrapolated) at zero time ( $B$ ,  $B'$ ), half-life ( $t_{1/2}$ ), elimination rate constant ( $\beta, \beta'$ ), volume of distribution ( $V_{d(\text{area})}$ ), area under the concentration curve (AUC), total body clearance ( $Cl_B$ ), absorption rate constant ( $k_{ab}$ ), percentage penetration of metronidazole into tissue cage fluid, percentage of drug absorbed into the systemic circulation following IM administration ( $F$ ), and the total amount of drug which was absorbed into the systemic circulation (in mg/kg).

Following IV administration of a 0.5% w/v solution of metronidazole at a dose rate of 20 mg/kg BWgt, the  $t_{1/2}$  at  $0.94 \pm 0.08$  per hour ( $n=8$ ) was rapid and consistent with a high figure for the elimination rate constant at  $0.79 \pm 0.09$  per hour ( $n=8$ ). The total body clearance, a more sensitive indicator of the biotransformation and excretion processes than  $t_{1/2}$ , was also rapid ( $0.32 \pm 0.06$  L/kg/hr) which is in keeping with the efficient drug metabolism of the goat. This may account for the low  $V_{d(\text{area})}$  which was unexpected for a basic drug of this nature in the ruminant.

Critical parameters for drug concentrations and durations of effect are summarized in Table I.

Metronidazole was rapidly detected in both sera and interstitial fluid (within 0.25 hrs) following the intramuscular administration of a 40% suspension of metronidazole at a dose rate of 20 mg/kg BWgt. The uptake of metronidazole from the injection sites differed markedly between individual goats, resulting in a mean absorption percentage of  $42.4\% \pm 8.8\%$  ( $n = 8$ ), equivalent to 8.4 mg/kg BWgt. Maximum serum levels were achieved within approximately one hour of IM administration, but the peak was more than ten-fold lower than the corresponding concentration found in serum following IV administration. Peak tissue cage drug concentrations were not achieved until four hours after IM administration.

The maximum drug concentration in tissue cage fluid was greater than the MIC upper threshold for a variety of anaerobic bacteria (12.5 mcg/ml), and this was maintained for 5.5 hrs. The lower limit of the MIC of 3.0 mcg/ml was exceeded for a correspondingly longer period.

TABLE I

Serum and tissue cage fluid drug concentrations and durations of effect, following administration of metronidazole solutions

Metronidazole (dose rate : 20 mg/kg BWgt)		C <sub>max</sub> mcg/ml	T <sub>max</sub> (hr)	Period that nominated serum conc. was exceeded (hr)		
				50 mcg/ml	12.5 mcg/ml	3.0 mcg/ml
0.5% w/v solution IV	serum	63.9 ± 12.2 (n=5)	<0.25 (n=5)	0.3 ± 0.05 (n=5)	1.4 ± 0.2 (n=8)	3.1 ± 0.2 (n=8)
	t.c.f	23.67 ± 4.46 (n=8)	1.41 ± 0.58 (n=8)	0	1.5 ± 0.6 (n=6)	7.9 ± 1.0 (n=8)
40% w/v suspen- sion IM	serum	5.5 ± 0.8 (n=8)	1.06 ± 0.6 (n=8)	0	0	4.1 ± 0.7 (n=8)
	t.c.f	13.2 ± 3.9 (n=8)	4.1 ± 0.7 (n=8)	0	5.0 ± 1.5 (n=5)	8.6 ± 1.6 (n=7)

t.c.f Tissue cage fluid

Further pharmacokinetic analysis of the experimental data made it possible to calculate specific medication schedules for the goat. These were established on the basis that serum metronidazole concentrations should be maintained at a level which was bactericidal for the majority of anaerobic bacteria, which included Bacteroides spp., Fusibacterium spp., and Clostridia spp. The recommendation given was that 0.5% w/v metronidazole solution should be administered at a dose rate of 20 mg/kg BWgt and repeated every 4-6 hrs. Using the 40% w/v metronidazole suspension, the dose rate should be 45 mg/kg BWgt and the medication should be repeated every 10-12 hrs. In each case the loading dose was only fractionally greater at 20.3 mg/kg BWgt and 48.5 mg/kg BWgt respectively.

The drug concentration in interstitial fluid (tissue cage fluid), gave some indication of the antimicrobial activity in extravascular tissues, a feature which can not be extrapolated from a profile of serum concentrations.

## ACKNOWLEDGEMENTS

I wish to thank my supervisors for their encouragement and assistance during this study. In particular, I thank Dr Brian Cooper for his guidance in pharmacokinetics and in the preparation of this manuscript, and Professor Neil Bruere for his interest and advice.

I gratefully acknowledge the assistance of the following people:

- Mrs Linda Dickson and Ms Hilary Burbidge for their help during the surgical procedure for tissue cage implantation,
  - Miss Debbie Lovelock, for restraint of the animals during the sample collection periods,
  - Mrs Elizabeth Davies, for tests performed on serum and tissue cage fluid,
  - Mr Bryan McKay, Professor Roger Morris, Dr Will Marsh and Mr Barry Butler for their advice on the use of the computer for the linear regression analysis and graphical display,
  - Dr D Palmer and Professor R D Jolly for their valued assistance with the HPLC analysis of samples.
  - Dr Lyndon Badcoe for the microscopic examination of the cage tissue,
  - and May & Baker (NZ) Ltd., for kindly supplying the metronidazole preparations, and relevant literature.
- and grateful acknowledgment to Mr Tom Law in producing the photographic material.

## TABLE OF CONTENTS

	<b>Page</b>
Abstract	ii
Acknowledgements	v
List of tables	vii
List of figures	viii
List of plates	ix
<u>Chapter 1</u> General introduction	1
<u>Chapter 2</u> Anaerobic bacteria and associated infections : a review of the literature	3
<u>Chapter 3</u> Metronidazole : a review of the literature	12
<u>Chapter 4</u> Methods of measuring the concentration of drugs outside the vascular compartment	25
<u>Chapter 5</u> Determination of the disposition of metronidazole in goats	28
<u>Chapter 6</u> General discussion and summary	56
References	64
<u>Appendix I</u> Materials and methods	75
<u>Appendix II</u> Plots of metronidazole concentration in serum and tissue cage fluid of seven goats, periods up to 24 hours after IV administra- tion of 0.5% w/v metronidazole solution	88
<u>Appendix III</u> Plots of metronidazole concentration in serum and tissue cage fluid of seven goats, at periods up to 24 hours after IM adminis- tration of 40% w/v metronidazole suspension	89

## LIST OF TABLES

Table		Page
3 : I	Disposition values in lactating cattle and sheep following intraperitoneal or intrauterine administration of 0.5% w/v metronidazole solution (expressed as mean $\pm$ standard deviation)	19
4 : I	Materials, procedures and anatomical sites involved in the determination of "interstitial fluid" drug concentrations	26
5 : I	Mean total protein in sera and tissue cage fluid	40
5 : II	Mean differential cell counts from pooled tissue cage fluid	41
5 : III	Least squares linear regression analysis following intravenous administration of 0.5% w/v metronidazole solution (Dose 20 mg/kg BWgt)	45
5 : IV	Pharmacokinetic values for the disposition of metronidazole in goat tissue cage fluid, following the intravenous administration of 0.5% w/v solution (Dose 20 mg/kg BWgt).	48
5 : V	Pharmacokinetic values for the disposition of metronidazole in goat sera, following the intravenous administration of 0.5% w/v solution (Dose 20 mg/kg BWgt)	49
5 : VI	Pharmacokinetic values for the disposition of metronidazole in goat sera fluid following the intramuscular administration of 40% w/v metronidazole suspension (Dose 20 mg/kg BWgt)	50
5 : VII	Pharmacokinetic values for the disposition of metronidazole in tissue cage fluid following the intramuscular administration of 40% w/v metronidazole suspension (Dose 20 mg/kg BWgt)	51
5 : VIII	Least squares linear regression analysis following intramuscular administration of 40% w/v metronidazole solution (Dose 20 mg/kg BWgt)	52
5 : IX	Recommendations for metronidazole administration schedules in the goat	55
App. I:1	Time intervals between the taking of blood or tissue cage fluid samples in goats following IV or IM injection of a 0.5 w/v solution or a 40 w/v suspension respectively of metronidazole	78

## LIST OF FIGURES

Figure		Page
3 : 1	Chemical structure of enteromycin	14
3 : 2	Chemical structure of azomycin (2-nitroimidazole)	14
3 : 3	Chemical structure of metronidazole (1-hydroxyethyl-2-methyl-5-nitroimidazole)	15
3 : 4	Chemical structure of dimetridazole (1, 2-dimethyl-5-nitroimidazole)	15
5 : 1	Diagrams of the right (a) and left (b) sides of a goat, showing the anatomical sites where the tissue cages were implanted subcutaneously. The numbers indicate the random order of tissue cages from which the fluid samples were collected	32
5 : 2	Sequence of events involved in the determination of metronidazole disposition kinetics in goats	38
5 : 3	Metronidazole concentration in serum and tissue cage fluid of goat Dopey (Do), following intravenous administration of 0.5% w/v metronidazole solution (serum metronidazole concentration = $61.52 + 0.26 \text{ time} + e$ )	46
5 : 4	Metronidazole concentration in serum and tissue cage fluid for goat Happy (Ha), following intramuscular administration of 40% w/v metronidazole solution (serum metronidazole concentration = $3.89 + 0.06 \text{ time} + e$ )	53
App. I:1	Semilogarithmic plot of plasma drug concentration versus time following administration of a single intravenous dose. Graphical technique for estimating the half-life of a drug is illustrated (from Baggot, J.D. [1977]): <u>Principles of Drug Disposition in Domestic Animals</u> . Published by Saunders Company, London.	83
App. I:2	Diagrammatic representation of the trapezoidal method used to calculate the area under the plasma concentration time-curve (AUC). (From Baggot, J.D. [1978]): J. vet. Pharmacol. Therap. 1: 111-118.	83

## LIST OF PLATES

Plate		Page
5 : 1	Six of the animals used in the experiment	30
5 : 2	Materials used in the manufacture of tissue cages	31
5 : 3	Series of steps involved in the surgical implantation of the tissue cages	33
5 : 4	Series of steps involved in the removal of the implanted tissue cages	36
5 : 5	Straw-coloured samples of tissue cage fluid	39
5 : 6	Sectioned tissue cage after removal, showing the tissue mass within the cage and fibrous attachments extending through the perforations of the tube	42
5 : 7	Necrotic core within an infected tissue cage	44
6 : 1	Exposure of an implanted tissue cage, to show the thick fibrous capsule	59